Loading data for GERN — first visit, this takes a few seconds.
Geron Corporation (GERN)
NasdaqGS: GERN
· Real-Time Price · USD
1.51
-0.02 (-1.31%)
At close: Aug 28, 2026, 3:59 PM
1.51
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Geron Corporation (GERN) Stock Price, Analysis & Data
-1.31% (1D)
| Bid | 1.31 |
| Market Cap | 970.13M |
| Revenue (ttm) | 204.56M |
| Net Income (ttm) | -67.61M |
| 0.59 | |
| -0.11 | |
| n/a | |
| 37.75 | |
| P/B (ttm) | 4.44 |
| P/S (ttm) | 4.74 |
| Earnings Date | May 6, 2026 |
| Ask | 1.73 |
| Volume | 7,331,336 |
| Avg. Volume (20D) | 11,547,400 |
| Open | 1.52 |
| Previous Close | 1.53 |
| Day's Range | 1.49 - 1.53 |
| 52-Week Range | 1.04 - 2.01 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 1996
Employees 258
Stock Exchange NasdaqGS
Ticker Symbol GERN
Website https://www.geron.com
Financial Performance
In 2025, Geron's revenue was 183.88M, an increase of 138.83% compared to the previous year's 76.99M. Earnings were -83.5M, a decrease of -52.17%.
Financial StatementsEarnings Surprise
Geron has released their quarterly earnings on Aug 5, 2026:
- Revenue of $57.48M misses estimates by $0, with 17.22% YoY growth.
- EPS of -0.02 misses estimates by -0.01, with 33.33% YoY growth.
Geron Corporation is scheduled to release its earnings on May 6, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2